The latest Policy Development Update highlights a number of papers due before the end of 2019:
- feedback on the investment platforms market study remedies;
- policy proposals on regulatory fees and levies;
- permitted links in relation to Patient Capital review;
- possible policy statement on general insurance value measures reporting;
- policy statement on overdraft pricing remedies and competition remedies as part of the high cost credit review
- consultation on price discrimination in the cash savings market; and
- policy statement on illiquid assets and open-ended funds.